TABLE 3.
Performance of the assays stratified by carbapenemase variant
| Carbapenemase | No. of isolatesa |
|||||||
|---|---|---|---|---|---|---|---|---|
| β-Carba |
bcCarba NP |
NeoRapid CARB |
bcCIM |
|||||
| P | N | P | N | P | N | P | N | |
| Ambler class D (n = 34) | ||||||||
| OXA-48 (n = 25) | 25 | 25 | 25 | 25 | ||||
| OXA-162 (n = 2) | 2 | 2 | 2 | 2 | ||||
| OXA-181 (n = 2) | 2 | 2 | 2 | 2 | ||||
| OXA-204 (n = 1) | 1 | 1 | 1 | 1 | ||||
| OXA-232 (n = 2) | 2 | 2 | 2 | 2 | ||||
| OXA-244 (n = 2) | 2 | 1 | 1 | 1 | 1 | 2 | ||
| Total (n [%]) | 34 (100) | 33 (97.1) | 1 (2.9) | 33 (97.1) | 1 (2.9) | 34 (100) | ||
| Ambler class A (n = 18) | ||||||||
| KPC-2 (n = 17) | 17 | 17 | 17 | 17 | ||||
| KPC-3 (n = 1) | 1 | 1 | 1 | 1 | ||||
| Total (n [%]) | 18 (100) | 18 (100) | 18 (100) | 18 (100) | ||||
| Ambler class B (n = 50) | ||||||||
| NDM-1 (n = 19) | 19 | 19 | 19 | 19 | ||||
| NDM-7 (n = 1) | 1 | 1 | 1 | 1 | ||||
| VIM-1 (n = 18) | 18 | 18 | 18 | 18 | ||||
| VIM-2 (n = 3) | 3 | 3 | 3 | 3 | ||||
| VIM-4 (n = 2) | 2 | 2 | 2 | 2 | ||||
| VIM-27 (n = 1) | 1 | 1 | 1 | 1 | ||||
| VIM-39 (n = 1) | 1 | 1 | 1 | 1 | ||||
| GIM-1 (n = 5) | 5 | 5 | 5 | 5 | ||||
| Total (n [%]) | 50 (100) | 50 (100) | 50 (100) | 50 (100) | ||||
| OXA-48 plus NDM-1 (n = 2) | 2 | 2 | 2 | 2 | ||||
| Total (n [%]) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | ||||
| Total carbapenemase positive (n [%]) | 104 (100) | 103 (99.0) | 1 (1.0) | 103 (99.0) | 1 (1.0) | 104 (100) | ||
| No carbapenemases (n = 81) | ||||||||
| Total carbapenemase negative (n [%]) | 4 (4.9) | 77 (95.1) | 4 (4.9) | 77 (95.1) | 7 (8.6) | 74 (91.4) | 81 (100) | |
a
P, positive result; N, negative result.